Is Vaxfab Enterp. overvalued or undervalued?

As of 17 November 2025, Vaxfab Enterprises has moved from a fair to a very attractive valuation grade. The company is currently considered undervalued, supported by a PE ratio of 4.69, an EV to EBIT of 3.44, and a remarkable ROCE of 61.79%. In comparison to peers, Vaxfab's valuation metrics stand out significantly; for instance, Elitecon International has a PE ratio of 294.38, while PTC India, another attractive peer, has a PE ratio of 7.56.
The company's strong performance is further underscored by its PEG ratio of 0.02, indicating substantial growth potential relative to its price. Despite a recent dip in stock price, Vaxfab has demonstrated impressive returns year-to-date at 247.66%, significantly outperforming the Sensex's 8.72% during the same period. Overall, the compelling valuation ratios and robust performance metrics suggest that Vaxfab Enterprises is indeed undervalued in the current market.